NANOMICRO(SH:688690)2024-11-22 09:37Group 1: Investor Relations Activities - The investor relations activities included specific object research, analyst meetings, media interviews, performance briefings, press releases, roadshows, and online meetings [2] - Participants included representatives from Zheshang Securities, Minsheng Securities, Tianhong Fund, Huatai Securities, Ping An Securities, and Ping An Pension [2] - The activities took place from November 19 to November 21, 2024, in the company meeting room [2] Group 2: Company Performance Insights - The third-quarter report for 2024 was discussed, focusing on operational management, product development, market expansion, and team integration [2] - The company anticipates growth in the macromolecule application direction, particularly in antibody new drug projects, with a focus on expanding recombinant proteins, nucleic acids, and blood products [2] - There is an increasing trend of domestic substitutes for imported products, with opportunities for repeat orders as new drug projects transition to commercial production [2] Group 3: Instrumentation Strategy - The acquisition of Saipu Instruments and Fuli Instruments aims to create a comprehensive chromatography technology platform, providing competitive overall solutions [2] - The company is integrating its "materials + instruments" marketing team to enhance service and understand customer project needs, thereby expanding the "aftermarket" application opportunities for consumables [2]